Supplemental Oxygen in Pulmonary Fibrosis

National Jewish Health

Status: Completed

Conditions: Pulmonary Fibrosis

Study type: Observational

Funder types: Other

Identifiers

NCT01961362

PCORI 4134a

Details and patient eligibility

About

To enhance understanding of supplemental oxygen-its utility in and adoption by patients with pulmonary fibrosis-by examining how patients perceive it and by determining how perceptions and patient-centered outcome measures change from before to after supplemental oxygen is prescribed.

Full description

The investigators aim to recruit patients with PF to participate in interviews and/or a one-year study of supplemental oxygen (O2). In the one-year study, the investigators will collect data before and for one year after PF patients are prescribed daily-use supplemental oxygen and compare outcomes, including shortness of breath, quality of life, fatigue, cough, and day-to-day functioning before and after O2.

Enrollment: 19 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Patient-Participants

(Using daily 02 therapy at time of enrollment)

• Diagnosis of PF
• Able to read and speak English
• Has been on daily-use supplemental oxygen for more than one year

(Not using daily 02 therapy at time of enrollment)

• Diagnosis of PF
• Able to read, speak and write in English
• Has not been prescribed daily-use supplemental oxygen
• Forced vital capacity <75% and diffusing capacity <65% of predicted values
• Subject's physician allows the subject to abstain from daily-use supplemental oxygen for 7-10 days after prescription to allow data for collection

Primary Supporters

• Self-report status of providing care or support to a person living with pulmonary fibrosis who has used supplemental oxygen for more than one year
• Able to speak English

O2 Prescribers

• Self-report status of being a prescriber of daily-use supplemental oxygen to PF patients
• Able to speak English

Exclusion criteria

Patient-Participants (Using daily 02 therapy at time of enrollment)

• No diagnosis of PF
• Unable to read and speak English
• Has been on daily-use supplemental oxygen for less than one year

(Not using daily 02 therapy at time of enrollment)

• No diagnosis of PF
• Unable to read, speak and write in English
• Using supplemental oxygen during the day
• Subject's physician does not allow the subject to abstain from daily-use supplemental oxygen for 7-10 days after prescription to allow data for collection

Primary Supporters • Not meeting inclusion criteria

O2 Prescribers

• Not meeting inclusion criteria

Trial design

19 participants in 1 patient group

Pulmonary fibrosis patients

Description:

Patients with pulmonary fibrosis of any cause (idiopathic, connective tissue disease, chronic hypersensitivity pneumonitis)